Leukaemia (lymphocytic) - fludarabine (TA29)
Fast, easy summary view of NICE guidance on 'blood and bone marrow cancers'
NICE has recommended that people with B-cell chronic leukaemia (CLL) who have had to stop their first chemotherapy treatment (for example because it was causing side effects or becasue their disease had progressed), may be treated with fludarabine tablets. Fludarabine may be introduced at the stage where poeple with CLL have previously been offered one of the following treatments:
- cyclophosphamide, doxorubicin, and prednisolone (CHOP)
- cyclophosphamide, doxorubicin and prednisolone (CAP), or
- cyclophosphamide, vincristine and prednisolone (CVP)
People with CLL should only be given fludarabine by a drip when their condition is such that they are unable to take the tablets.
- TA29 Leukaemia (lymphocytic) - fludarabine: Summary
- TA29 Leukaemia (lymphocytic) - fludarabine: Guidance (html)
- TA29 Leukaemia (lymphocytic) - fludarabine: Guidance (web format)
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: blood and bone marrow cancers
- TA29 Leukaemia (lymphocytic) - fludarabine: review decision - December 2013
- TA29 Leukaemia (lymphocytic) - fludarabine: review proposal - October 2013
- Review decision
- Review proposal
- Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia: Cost-effectiveness annexe
- Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia: Effectiveness annexe
- Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia - HTA report (main)
This page was last updated: 14 January 2014
Information for the public
Implementation tools and resources
- None available
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.